Background
Methods
Study design and treatment
Biomarker analyses
Statistical analyses
Results
Patient characteristics
Dynamic types of plasma L858R mutations
Characteristics | Ascend group (n, %) | Stable group (n, %) |
P
|
---|---|---|---|
Gender | 0.346 | ||
Male | 30 (49.2) | 7 (36.8) | |
Female | 31 (50.8) | 12 (63.2) | |
Age (median, range) | 62 (40~84) | 69 (40~84) | 0.362 |
Body weight loss | 1.000 | ||
<5 % | 58 (95.1) | 19 (100.0) | |
≥5 % | 3 (4.9) | 0 (0.0) | |
Smoking status | 0.401 | ||
Never-smokers | 41 (67.2) | 15 (78.9) | |
Smokers | 20 (32.8) | 4 (21.1) | |
ECOG PS | 1.000 | ||
0~1 | 58 (95.1) | 18 (94.7) | |
≥2 | 3 (4.9) | 1 (5.3) | |
Pathology | 1.000 | ||
Adenocarcinoma | 58 (95.1) | 18 (94.7) | |
Non-adenocarcinoma | 3 (4.9) | 1 (5.3) | |
Clinical stage | 1.000 | ||
IIIB | 1 (1.6) | 0 (0.0) | |
IV | 60 (98.4) | 19 (100.0) | |
Line of EGFR-TKI | 0.371 | ||
First-line | 36 (59.0) | 9 (47.4) | |
≥Second-line | 25 (41.0) | 10 (52.6) | |
EGFR-TKI | 0.946 | ||
Erlotinib | 23 (37.7) | 7 (36.8) | |
Gefitinib | 38 (62.3) | 12 (63.2) | |
Basic level of plasma L858R mutation (median, range) | 20.0 (0.97~109.43) | 27.45 (3.56~112.9) | 0.184 |
Clinical outcomes
Variables |
B
| SE | Wald |
P
| HR | 95.0 % CI for HR |
---|---|---|---|---|---|---|
Pathology | ||||||
Non-adenocarcinoma | 1.00 | |||||
Adenocarcinoma | −1.26 | 0.54 | 5.36 | 0.021 | 0.285 | 0.10~0.83 |
ECOG PS | ||||||
≥2 | 1.00 | |||||
0–1 | −1.01 | 0.53 | 3.71 | 0.054 | 0.363 | 0.13~1.02 |
Groups | ||||||
Stable group | 1.00 | |||||
Ascend group | −0.70 | 0.28 | 6.43 | 0.011 | 0.498 | 0.30~0.85 |